Infectivity of the mouse mammary tumour virus (MMTV) is inhibited by mouse APOBEC3 (mA3) which is efficiently packaged into virions. As the inhibition is only partial, the virus can replicate in tissues expressing mA3 and complete its replication cycle. Here, we have examined the sensitivity of MMTV to inhibition by a human orthologue of mA3, A3G. We report that the virus containing A3G is only moderately susceptible to inhibition by the human factor. Whereas the vif-deficient HIV-1 vector produced in human epithelial cells expressing endogenous levels of A3G was efficiently inhibited, an MMTV vector remained fully infectious. Greater A3G expression levels were necessary to restrict infectivity of MMTV, but only when the factor retained its deaminase activity. Furthermore, the spreading kinetic of a replication competent MMTV was only moderately accelerated in cells with downmodulated A3G expression. These data suggest that MMTV has evolved a mechanism to neutralize antiviral activity of APOBEC3 proteins.
Viruses that persist in their host are often not highly pathogenic because their infectivity is inhibited by host antiviral responses including innate immunity factors such as APO-BEC3 proteins (A3). The prototypic human (A3G) and mouse A3 (mA3) proteins are incorporated into progeny virions and transmitted with the virus to target cells [1, 2] . There, they restrict the retroviral life cycle by inhibiting the infection through the extensive deamination of deoxycytidine on the transiently exposed DNA minus strand during reverse transcription (RT). The hypermutation is then registered as G-to-A changes in the newly synthesized plusstrand viral DNA [3] [4] [5] [6] . A second, still debated, mechanism of inhibition, which is independent of the extensive viral DNA editing, has also been reported. The deaminase-independent means of inhibition include an interference with the initiation and the elongation of RT as well as the inhibition of integration [7] [8] [9] [10] .
One of the viruses whose infectivity is inhibited by A3 proteins is the mouse mammary tumour virus (MMTV). MMTV was the first virus shown to be inhibited by mA3 in vivo [2] . mA3 knockout mice were more susceptible to virus infection than their mA3 +/+ littermates. Spread of the milkborn MMTV to lymphatic organs and ultimately to the mammary gland, was more rapid and extensive in mice lacking mA3 [11] . The seminal in vivo work also showed that mA3 provides only a partial protection to mice against infection with MMTV and raised a question of how the virus counteracts the deleterious effect of the innate immunity factor [2] . The mA3 was efficiently packaged to the cores of MMTV virions and retained its cytidine deamination activity as demonstrated in an in vitro deaminase assay [7] . Interestingly, however, only a low overall G-to-A mutation rate was detected in proviral sequences obtained from infected wild-type (mA3 +/+ ) mice and from ex vivo reverse transcribed MMTV DNA made from milk-derived viruses containing packaged mA3 [2, 7] . Furthermore, it has been reported that the rate of RT was slower in virions obtained from the milk of mA3 +/+ compared to mA3 À/À mice. Based on this evidence it has been proposed that the major means by which mA3 restricts MMTV infection is through inhibition of the early RT [7] .
Inhibition of MMTV infectivity has also been demonstrated for the human orthologue of mA3, A3G. Like mA3, the human restriction factor, overexpressed in MMTV-GFP vector producers, was packaged into MMTV virions and exerted anti-MMTV activity that was comparable to the mouse counterpart and that resulted in an incomplete restriction of MMTV infectivity [2] . Recently, we showed that various strains of MMTV can productively infect non-murine cell lines including those of human origin [12] [13] [14] . A cell line (Hs578T) exhibiting a relatively high sensitivity to MMTV infection was derived from human breast tissue. Interestingly, this line has been reported to express A3G [11] . The A3G expression level was sufficient to exert an antiviral function on the HIV-1 virus produced in the absence of Vif [11] . This raised the question of the extent to which A3G produced in Hs578T cells restricts the infectivity of MMTV.
To address this question, we generated a derivative of the Hs578T cell line, named Hs578T-DA3G, stably expressing a shRNA directed against the A3G mRNA (GIPZ Lentiviral shRNA System) that results in a knock-down of A3G expression in these cells as evidenced by qRT-PCR and Western blot analyses (Fig. 1a, b) . As a control, we generated a cell line, Hs578T-NS, stably expressing a non-silencing shRNA and producing the same A3G amount as the parental line (Fig. 1a, b) . Next, we sought to determine how the expression of endogenous A3G levels in Hs578T cells affects the infectivity of MMTV. We performed a single-round infection experiment using a egfp gene-containing MMTV that was produced in the cells containing and lacking A3G proteins, Hs578T-NS and Hs578T-DA3G, respectively. The cells seeded in a six well plate (3Â10 5 cells per well) were cotransfected with a transfer vector pRRpCeGFPWPRE25 (1 µg), a packaging construct pCMVgpRRE17 (0.8 µg), a helper Rev-expressing construct (0.6 µg) and finally with a plasmid bearing VSV-G env (0.3 µg) [15] . Viral stocks were collected 2 days after transfection, filtered and used for transduction of target HeLa cells seeded at a density of 5Â10 4 cells per well. As a control vif-deficient HIV-1 (HIV1DVif, also carrying egfp gene), known to be inhibited by endogenous levels of A3G expressed in the Hs578T cells, was used [11] . Consistent with previously published results, the HIV-1DVif virions produced in the presence of A3G were significantly less infectious than the virus produced in the absence of A3G. Approximately, threefold less EGFPpositive cells were detected by flow cytometry when the virus was generated in the Hs578T-NS cells compared to the virus produced in the Hs578TDA3G (Fig. 1c) . Thus, the endogenous A3G levels are sufficient to restrict the infectivity of HIV-1DVif virions. In sharp contrast to HIV-1, infectivity of the MMTV produced in the A3G-positive cells did not differ from infectivity of the virions produced in the A3G knock-down cells (Fig. 1c) . These results strongly suggest that MMTV is less sensitive to A3G-mediated restriction of virus infectivity.
To further corroborate the single-round infection results, we monitored a spreading kinetic of two replication-competent MMTV strains in Hs578T cells containing or lacking A3G. The MMTV(GR) and MMTV(C3H) virus was produced from GR and Mm5MT cells, respectively, as described previously [12, 13] . The viruses were harvested from supernatants of dexamethasone-stimulated cells (DEX; 10 À6 M; DEX induces the MMTV promoter), filtered and then used to infect the Hs578T-DA3G or Hs578T-NS cells [seeded 1 day before infection at a density of 2Â10 4 cells per well (six-well plate)]. Infected cells were cultured for 7 weeks in the presence of DEX (10 À6 M) and the MMTV proviral loads were monitored by a real-time TaqMan PCR with primers targeting the env gene as described before [12] . We reasoned that if the A3G protein produced in Hs578T cells is sufficient to inhibit the infectivity of MMTV, this sensitive assay should show a faster rate of spreading in the A3G knock-down cells compared to the A3G positive cells. Consistent with our previous observations [12, 13] , proviral loads increased at later cultivation time points in Hs578T producing endogenous A3G levels (Hs578T-NS). This was observed for both MMTV(GR) (Fig. 1d ) and MMTV(C3H) (Fig. 1e ) strains. Importantly, qPCR revealed only a modest increase in the rate of spreading of the two strains in Hs578T-DA3G compared to A3G-containing cells. This was indicated by slightly elevated proviral loads at later cultivation time points in these cells (Fig. 1d, e) . Collectively, these data suggest that, although MMTV does exhibit some sensitivity to endogenous A3G levels found in Hs578T cells, these levels are not sufficient to restrict MMTV infectivity and prevent its spread in Hs578T cells. It also further supports the concept that MMTV is somewhat more resistant to the A3G protein than Vif-deficient HIV-1.
To find out whether greater levels of A3G restrict the MMTV infectivity, we conducted a dose escalation study. 293 T cells expressing increasing amounts of A3G were used for the MMTV-eGFP production. The cells seeded in a sixwell plate (1Â10 6 cells per well) were co-transfected with the plasmids required for the production of the egfp-containing virus together with various amounts (0, 10, 40, 160 ng) of an A3G expression construct. Total DNA content was adjusted to 3 µg with a parental 'empty' plasmid. Replication-incompetent recombinant virus stocks were collected 2 days after transfection, filtered and used for transduction of Hela cells. Consistent with our previous results, production of the virions in cells containing low levels of A3G did not lead to a reduction of the MMTV infectivity. Reduced infectivity was observed when the virus-producing cells expressed A3G protein at levels greater than those found in IM-9 lymphoblasts, i.e. after transfection with at least 40 ng of the A3G expression construct (Fig. 2a, b) . Taken together, these data show that MMTV is inhibited by A3G. However, a relatively high A3G amount is required to exert anti-MMTV function.
Next, we determined whether the proviral plus DNA strands carry A3G-mediated G-to-A changes. We performed a largescale sequencing on a~400 bp-long segment of a Woodchuck post-transcriptional regulatory element (WPRE) region present upstream of the polypurine tract (PPT). As this region remains single-stranded during reverse transcription for the longest period of time, it represents a good target for the evaluation of A3G-directed mutagenesis. The genomic DNA was extracted from cells transduced with vector particles produced in cells transfected with 40 ng of the A3G expression plasmid. The MMTV-eGFP particles exhibited approximately 17 % lower infectivity compared to virions produced in the absence of A3G (Fig. 2a) Hs578T ∆hA3G
Hs578T NS HEK293T Fig. 1 . Differential sensitivities of MMTV and HIV-1DVif to endogenous levels of A3G expressed in Hs578T cells. The expression of A3G was knocked down using a lentivector expressing shRNA directed against A3G mRNA. (a) The A3G mRNA expression levels in untreated, non-silencing shRNA-, anti-A3G shRNA-treated cells and finally in control cells was determined by qRT-PCR using 200 ng of total RNA and A3G-specific primers hA3G_F: (TCA GAG GAC GGC ATG AGA CTT AC) and hA3G_R (AGC AGG ACC CAG GTG TCA TTG). GAPDH-specific primers (ATG GCT CCT GCA CCA CCA AC and CGC CTG CTT CAC CAC CTT CT) were used to assess a fold change in gene expression levels by using the DCt method [26] . 
in Hs578T cells infected with MMTV(GR) (c) or MMTV(C3H) (d).
A real-time TaqMan PCR with env-specific primers was performed as described before [12] . Equal loading of the PCR reactions was monitored by a real-time TaqMan PCR specific for the APOB gene (c, d) [12] .
results are summarized in Table 1 . We found that the frequency of G-to-A mutations was rather low (0.15 per 100 bp) but it was significantly higher (3.8-fold; 2 
test, P=5Â10

À13
) in proviral sequences generated by virus particles carrying A3G than in MMTV-eGFP proviruses produced by virions lacking A3G. Taken together, the results show that the reduction of MMTV infectivity by A3G is accompanied by G-to-A mutation. Given that the used amount of A3G caused only a small reduction of virus infectivity, it seems conceivable that the frequency of mutations is proportional to the level of inhibition.
The significance of the editing-dependent versus enzymatic activity-independent mode of inhibition of retroviral infectivity is a matter of some controversy. Some groups argue that the deaminase-independent activity is biologically relevant, whereas others regard the non-enzymatic restriction as an artefact of experimental conditions [16] . The editingindependent mode of restriction has also been reported as the underlying mechanism responsible for reduction of MMTV infectivity [7] . To clarify whether the enzymatic activity of A3G is necessary for restriction of MMTV, we performed complementary experiments to analyse the inhibition of infectivity of the MMTV-eGFP particles produced in the presence of an A3G variant deficient in deaminase activity (A3G-E259Q) [17] . Knowing the dose of A3G protein necessary for anti-MMTV function, we sought to determine whether the same amount of a deoxycytidine deaminase-deficient A3G protein interferes with the MMTV infectivity. The MMTV-eGFP virions were prepared as described above either in the presence of the wildtype or enzymatically inactive A3G. We used 0.2 µg of the A3G expression constructs as this amount efficiently inhibited MMTV infectivity (by approximately twofold) in the initial dose-response analysis. We reasoned that if the deaminase-independent means of inhibition is the primary inhibitory mode, we should observe a similar inhibition of MMTV infectivity with the mutant A3G. The results depicted in Fig. 2 show that the mutant A3G-E259Q, although expressed at the same levels as wild-type A3G (Fig. 2d ) and packaged to virions (Fig. 2d) , did not reduce MMTV-eGFP infectivity (Fig. 2c ). An inhibition was only observed when 1 µg of the A3G expression plasmid was cotransfected to the virus-producing cells. From these data and in combination with the aforementioned sequencing analysis, we concluded that deoxycytidine deaminase activity is required for inhibition of MMTV infectivity by A3G.
This result was surprising to us as it contradicts the previous suggestion that the editing-independent mechanism is the major mode of A3-mediated restriction of MMTV infectivity. We can only surmise what accounts for the contradicting conclusions. It may be possible that there is a fundamental difference in the mechanism by which the human and mouse innate immunity factor exert their antiviral functions on MMTV. However, the betaretrovirus shows the same response to increasing amounts of mA3 and A3G [2] . Therefore, the two mechanisms would have to exhibit the same magnitude of inhibition. As it seems rather unlikely, we prefer the concept that both A3s use the same inhibitory mode. Thus, different conclusions may be due to differences in methodology or interpretation of results. Whereas the data reported here were obtained with the MMTV-eGFP virus produced analogously as described for the third generation of lentiviral vector systems (splitgenome-design approach) [15, 18] , previous data were obtained with an MMTV-eGFP derived from a single complete molecular clone containing the egfp gene in the LTR (pGR102ES; also produced in our laboratory) and exhibiting approximately 1000-fold lower infection titres than 'the split-genome-design' virus [2, 15] . Additionally, the other studies worked with viruses isolated from milk or mammary tumours of MMTV-infected mice. Levels of isolated virus particles, containing or lacking endogenous mA3 amounts, were normalized using qRT-PCR and then used for assessment of RT kinetics. Subtle inaccuracies in the quantification/normalization may then be amplified in the following enzyme kinetic study. Further, for the sequencing analysis presented here, we quantified the G-to-A mutation rate in the WPRE region situated upstream of PPT, whereas others analysed the 3¢LTR and env regions [2, 7] . The reported lack of G-to-A mutation in the 3¢LTRs from viruses replicating in A3 +/+ mice [2] may be due to the fact that this region does not remain single-stranded for an extended period of time during RT. As a result, this region does not accumulate as many mutations as the regions that remain transiently single-stranded for a longer time (e.g. sequences upstream of PPT) [19] . The env region in the cDNAs produced in the presence of endogenous mA3 levels was reported to accumulate the G-to-A mutations with approximately the same frequency as reported here (0.21 vs 0.15 mutations per 100 bp) [7] . Thus, it appears that regardless of whether MMTV packages A3G or mA3, the overall G-to-A mutation rate is lower than that reported for viruses that are highly sensitive to inhibition by A3G, such as HIV1DVif. However, at least in the case of A3G, the low mutation frequency seems to be proportional to the level of inhibition. The infectivity of MMTV appears to be inhibited to a lesser degree than the infectivity of other retroviruses such as HIV-1 lacking Vif as shown by a direct comparison of responses to endogenous levels of A3G between MMTV and vif-deficient HIV-1 vectors. Whereas A3G expressed in Hs578T cells was capable of blocking HIV-1DVif infection, the same A3G levels were insufficient to neutralize the betaretrovirus (Fig. 1c) . Therefore, it appears that MMTV is able, to some extent, to resist the neutralization mediated by A3G. This observation is rather surprising as the general emerging pattern is that retroviruses that replicate in a given species are not highly sensitive to inhibition by A3 proteins present in relevant tissues of that species. However, they are often strongly restricted by A3s from other species [20] .
Collectively, given that MMTV is only partially inhibited by endogenous A3G protein levels and combined with the observation that proviruses in mA3 +/+ mice as well as proviruses produced by A3G-containig vector particles carry only a limited number of G-to-A substitutions [2, 7] , it appears that the betaretrovirus has evolved a mechanism preventing A3s from exerting their cytidine deaminasedependent antiviral activity. As the virus does not exclude A3G and mA3 proteins from virions [2] , the mechanism seems to be different from the escape modes reported previously [21] [22] [23] [24] [25] and occurs at a step subsequent to virus entry. Work to characterize the counteraction mechanism is currently ongoing.
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